Recent developments include completion of enrollment in the Phase 2 CLOVER study for metastatic colorectal cancer, initiation of an Expanded Access Program for triple-negative breast cancer, and a strategic collaboration with Natera for molecular response analysis. The company secured funding to launch the Expanded Access Program and appointed key clinical consultants.

• Completed enrollment in Phase 2 CLOVER study evaluating leronlimab in combination therapy for CCR5-positive metastatic colorectal cancer in April 2026 [S1].
• Initiated dosing of first participant in Expanded Access Program for triple-negative breast cancer patients in April 2026 [S1].
• Presented early interim data from CLOVER study at investor update call in April 2026 [S1].
• Entered strategic collaboration with Natera to analyze ctDNA and molecular response data from CLOVER study to inform development strategies [S1].
• Secured funding to launch Expanded Access Program for leronlimab in breast cancer as of January 2026 [N7].
• Appointed Richard Pestell as lead oncology consultant and Melissa Palmer as lead hepatology consultant, enhancing clinical expertise [N7, N8].

CytoDyn's leronlimab targets a novel mechanism in oncology by inhibiting CCR5, which is implicated in tumor progression and metastasis across multiple solid tumors. The company has advanced clinical trials in metastatic colorectal cancer and triple-negative breast cancer, with completed enrollment and early data presentations. Its Expanded Access Program and collaborations with Natera for ctDNA analysis may provide valuable clinical insights. Development of longer-acting formulations and ongoing patent protection could enhance commercial potential. Strategic partnerships may support funding and accelerate development.

CytoDyn is a clinical-stage biotech with no approved products and limited liquidity, holding a current ratio of 0.26 and cash of $11.85 million as of May 2026. The company reported significant net losses driven by clinical trial expenses. Its clinical programs face typical biotech risks including clinical trial outcomes, regulatory approvals, and competitive pressures. Funding needs may lead to dilution or restrictive covenants. The complexity of oncology drug development and reliance on partnerships add execution risk. Preclinical and early clinical data remain preliminary, and commercialization is uncertain.

CytoDyn's potential competitive advantage lies in its proprietary monoclonal antibody leronlimab, which targets the CCR5 receptor with a unique mechanism of action that may inhibit tumor metastasis and modulate immune responses. The company holds patents protecting leronlimab and is developing longer-acting formulations. Its clinical-stage pipeline and collaborations, including with Natera for molecular response analysis, support its development efforts. However, as a clinical-stage biotech, its moat depends on successful clinical validation, regulatory approvals, and commercialization, which remain uncertain.

• Clinical Development Risk: Leronlimab is in clinical trials with no approved indication; trial outcomes and regulatory approvals are uncertain.
• Financial Risk: The company has limited liquidity with a current ratio of 0.26 and ongoing net losses, requiring additional funding that may dilute shareholders or impose operational restrictions.
• Execution Risk: Advancing multiple clinical programs and collaborations requires effective management and sufficient resources; delays or failures could impact development.
• Competitive Risk: Other therapies targeting oncology indications may compete, and leronlimab's differentiation depends on clinical validation.

• CytoDyn Inc. is a clinical-stage biotechnology company focused on the clinical development of leronlimab, a humanized monoclonal antibody targeting the CCR5 receptor, for multiple therapeutic indications including solid-tumor oncology [S1].
• Leronlimab is being studied in Phase 2 clinical trials for relapsed/refractory microsatellite stable metastatic colorectal cancer (CLOVER study) and metastatic triple-negative breast cancer (mTNBC) [S1].
• The company completed enrollment in the CLOVER Phase 2 study with over 60 patients across multiple U.S. sites as of April 2026 [S1].
• CytoDyn has initiated an Expanded Access Program (EAP) for triple-negative breast cancer patients who have exhausted other treatment options, with initial dosing started in April 2026 [S1].
• The company collaborates with Natera, Inc. to analyze ctDNA and molecular response data from the CLOVER study to gain insights into disease progression and treatment response [S1].
• Leronlimab's mechanism involves blocking CCR5 receptor signaling, which is implicated in tumor progression, metastasis, immune regulation, and angiogenesis in various solid tumors including breast, colon, prostate, and pancreatic cancers [S1].
• The company has ongoing preclinical and clinical development efforts in glioblastoma multiforme (GBM) and is pursuing investigator-initiated pilot studies [S1].
• CytoDyn is developing longer-acting CCR5 antagonist molecules through a joint development agreement using generative AI drug discovery tools [S1].
• The company holds patents and pursues ongoing patent protection for leronlimab and related technologies [S1].
• Financial snapshot as of May 31, 2026: cash and equivalents of $11.85 million, current assets of $13.88 million, current liabilities of $53.73 million, resulting in a current ratio of 0.26 and cash ratio of 0.22 [S1].
• Net loss for fiscal year 2026 was $42.7 million with basic and diluted EPS of -$0.03 per share [S1].
• Operating expenses increased in fiscal 2026 compared to prior periods, driven by higher clinical trial costs, especially related to the Phase 2 colorectal cancer study [S2].
• The company has raised funding through equity and convertible notes, including a $30 million purchase agreement with Yorkville as of November 2025 [S1].
• CytoDyn's business strategy includes completing ongoing clinical trials, exploring additional solid tumor indications, and pursuing strategic partnerships to fund and advance clinical development [S1].
• Recent news highlights include securing funding to launch the Expanded Access Program for leronlimab in breast cancer (January 2026) [N7].
• The company appointed Richard Pestell as lead oncology consultant and Melissa Palmer as lead hepatology consultant, indicating focus on clinical expertise [N7, N8].